Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.

Engelke CG, Parsels LA, Qian Y, Zhang Q, Karnak D, Robertson JR, Tanska DM, Wei D, Davis MA, Parsels JD, Zhao L, Greenson JK, Lawrence TS, Maybaum J, Morgan MA.

Clin Cancer Res. 2013 Aug 15;19(16):4412-21. doi: 10.1158/1078-0432.CCR-12-3748. Epub 2013 Jun 26.

2.

Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.

Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA.

Neoplasia. 2015 Oct;17(10):757-66. doi: 10.1016/j.neo.2015.09.006.

3.

Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, Canman CE, Normolle DP, Zabludoff SD, Maybaum J, Lawrence TS.

Cancer Res. 2010 Jun 15;70(12):4972-81. doi: 10.1158/0008-5472.CAN-09-3573. Epub 2010 May 25.

4.

Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.

Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, Arumugarajah S, Parsels JD, Hylander-Gans L, Simeone DM, Morosini D, Brown JL, Zabludoff SD, Maybaum J, Lawrence TS, Morgan MA.

Clin Cancer Res. 2011 Jun 1;17(11):3706-15. doi: 10.1158/1078-0432.CCR-10-3082. Epub 2011 Apr 11.

5.

Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.

Venkatesha VA, Parsels LA, Parsels JD, Zhao L, Zabludoff SD, Simeone DM, Maybaum J, Lawrence TS, Morgan MA.

Neoplasia. 2012 Jun;14(6):519-25.

6.

Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.

Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence TS, Maybaum J.

Mol Cancer Ther. 2009 Jan;8(1):45-54. doi: 10.1158/1535-7163.MCT-08-0662.

7.

Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.

Montano R, Thompson R, Chung I, Hou H, Khan N, Eastman A.

BMC Cancer. 2013 Dec 21;13:604. doi: 10.1186/1471-2407-13-604.

8.

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.

Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, Vallis KA, Hammond EM, Olcina MM, Gillies McKenna W, Muschel RJ, Brunner TB.

Cell Death Dis. 2012 Dec 6;3:e441. doi: 10.1038/cddis.2012.181.

9.

Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair.

Wei D, Parsels LA, Karnak D, Davis MA, Parsels JD, Marsh AC, Zhao L, Maybaum J, Lawrence TS, Sun Y, Morgan MA.

Clin Cancer Res. 2013 Aug 15;19(16):4422-32. doi: 10.1158/1078-0432.CCR-13-0788. Epub 2013 Jun 18.

10.

Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.

Al-Ejeh F, Pajic M, Shi W, Kalimutho M, Miranda M, Nagrial AM, Chou A, Biankin AV, Grimmond SM; Australian Pancreatic Cancer Genome Initiative, Brown MP, Khanna KK.

Clin Cancer Res. 2014 Jun 15;20(12):3187-97. doi: 10.1158/1078-0432.CCR-14-0048. Epub 2014 May 16.

11.

LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.

Barnard D, Diaz HB, Burke T, Donoho G, Beckmann R, Jones B, Barda D, King C, Marshall M.

Invest New Drugs. 2016 Feb;34(1):49-60. doi: 10.1007/s10637-015-0310-y. Epub 2015 Nov 27.

PMID:
26612134
12.

Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.

Beeharry N, Banina E, Hittle J, Skobeleva N, Khazak V, Deacon S, Andrake M, Egleston BL, Peterson JR, Astsaturov I, Yen TJ.

Cell Cycle. 2014;13(14):2172-91. doi: 10.4161/cc.29214. Epub 2014 Jun 23.

13.

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, Hidalgo M.

Clin Cancer Res. 2011 May 1;17(9):2799-806. doi: 10.1158/1078-0432.CCR-10-2580. Epub 2011 Mar 9.

14.

Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.

Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, Maybaum J, Lawrence TS, Morgan MA.

Cell Cycle. 2011 Dec 15;10(24):4321-9. doi: 10.4161/cc.10.24.18661. Epub 2011 Dec 15.

15.

Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.

Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, Marsh KB, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA.

Clin Cancer Res. 2014 Oct 1;20(19):5085-96. doi: 10.1158/1078-0432.CCR-14-1038. Epub 2014 Aug 12.

16.

ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.

Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM.

Cancer Res. 2013 Jun 15;73(12):3683-91. doi: 10.1158/0008-5472.CAN-13-0110. Epub 2013 Apr 2.

17.

Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.

Nagaraj NS, Washington MK, Merchant NB.

Clin Cancer Res. 2011 Feb 1;17(3):483-93. doi: 10.1158/1078-0432.CCR-10-1670. Epub 2011 Jan 25.

18.

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.

Chaudhuri L, Vincelette ND, Koh BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH, Tibes R.

Haematologica. 2014 Apr;99(4):688-96. doi: 10.3324/haematol.2013.093187. Epub 2013 Oct 31.

19.

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S.

J Transl Med. 2009 Jun 11;7:43. doi: 10.1186/1479-5876-7-43.

20.

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).

Vena F, Li Causi E, Rodriguez-Justo M, Goodstal S, Hagemann T, Hartley JA, Hochhauser D.

Clin Cancer Res. 2015 Dec 15;21(24):5563-77. doi: 10.1158/1078-0432.CCR-15-0485. Epub 2015 Jul 30.

Supplemental Content

Support Center